Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors.

[1]  P. Ruszniewski,et al.  18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation , 2017, Neuroendocrinology.

[2]  Tonsok Kim,et al.  Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors. , 2015, Surgery.

[3]  C. Rowsell,et al.  Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  M. Cuggia,et al.  High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation , 2014, The Journal of Nuclear Medicine.

[5]  T. Höller,et al.  Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by 18F-FDG PET: Feasibility of a Metabolic Grading System , 2014, The Journal of Nuclear Medicine.

[6]  R. Goldin,et al.  Role of Ki-67 Proliferation Index in the Assessment of Patients with Neuroendocrine Neoplasias Regarding the Stage of Disease , 2014, World Journal of Surgery.

[7]  N. Heaton,et al.  Elevated Ki‐67 labeling index in ‘synchronous liver metastases’ of well differentiated enteropancreatic neuroendocrine tumor , 2013, Pathology international.

[8]  Run Yu,et al.  Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. , 2012, Human pathology.

[9]  Laura H. Tang,et al.  Effect of Tumor Heterogeneity on the Assessment of Ki67 Labeling Index in Well-differentiated Neuroendocrine Tumors Metastatic to the Liver: Implications for Prognostic Stratification , 2011, The American journal of surgical pathology.

[10]  T. de Baère,et al.  Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. , 2011, The Journal of clinical endocrinology and metabolism.

[11]  A. Kjaer,et al.  F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .

[12]  G. Baron,et al.  Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors , 2009, Modern Pathology.

[13]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.